文献速递前列腺癌

转移性去势抵抗性前列腺癌根治性前列腺切除术的可行性、安全性与生活质量结局

Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.
PubMed 文献 · Eur Urol · 2018-04-12

该研究分析了2008至2016年间14例在转移性去势抵抗性前列腺癌(mCRPC)背景下接受根治性前列腺切除术(RP)的患者。从mCRPC诊断到RP的中位时间为5.1个月(IQR 1.4-12.0)。术前和术后<3个月的中位EPIC泌尿功能QOL评分分别为84(IQR 70-95)和78(IQR 62-81)。术后并发症包括1例Clavien III级、3例II级和1例I级。结论认为在mCRPC患者中RP可行且仅伴有有限轻微并发症,但此应用仍高度处于研究阶段,除缓解症状外不应在临床试验外使用。

要点

  • mCRPC患者行RP可行,主要并发症为轻微(Clavien I-II级为主)。
  • 术后早期泌尿功能QOL评分较术前略有下降。
  • RP在mCRPC中仍属研究性治疗,除症状缓解外仅限临床试验。

核心结论

  • 在mCRPC患者中,根治性前列腺切除术可行且伴有有限轻微并发症。
  • 该治疗高度处于研究阶段,除症状缓解外不应在临床试验外使用。

研究设计与样本

  • 回顾性分析2008至2016年间14例在mCRPC背景下接受根治性前列腺切除术的患者。

主要发现

  • 从mCRPC诊断到RP的中位时间为5.1个月(IQR 1.4-12.0)。
  • 术前中位EPIC泌尿功能QOL评分为84(IQR 70-95),术后<3个月为78(IQR 62-81)。
  • 术后并发症包括1例Clavien III级、3例II级和1例I级。

临床怎么用

  • RP在mCRPC中的应用应限于临床试验或症状缓解目的。

局限性

  • 样本量小(14例),为回顾性分析,结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Ongoing prospective studies are evaluating treatment of the primary tumor in men with de novo metastatic prostate cancer (PCa). One potential benefit is prevention of morbidity from local progression. Thus, local therapy may be best applied selectively to men with local progression once resistance to first-line therapies has occurred. Here, we gather support for the hypothesis that radical prostatectomy (RP) is safe and preserves quality of life (QOL) when applied in men with metastatic castration-resistant PCa (mCRPC). We analyzed 14 patients who underwent RP in the setting of mCRPC from 2008 to 2016. Median time from mCRPC to RP was 5.1 mo (interquartile range [IQR] 1.4-12.0). Median preoperative and <3 mo postoperative Expanded Prostate Cancer Index Composite urinary function QOL scores were 84 (IQR 70-95) and 78 (IQR 62-81), respectively. There were one Clavien Grade III, three Grade II, and one Grade I complications postoperatively. In these patients with mCRPC, RP was feasible with limited minor complications. PATIENT SUMMARY: We report on a select group of men with metastatic castration-resistant prostate cancer who had prostatectomy. Prostatectomy is highly investigational in this setting and should not be used outside of a clinical trial other than for symptom relief.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Reichard CA, Gregg JR, Achim MF, et al. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. 2018. PMID: 29656854. doi:10.1016/j.eururo.2018.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。